REG - Nanosynth Group PLC - Successful Trial Results

NanosynthAnnouncement

31/08/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220831:nRSe6496Xa&default-theme=true

RNS Number : 6496X  Nanosynth Group PLC  31 August 2022

 

31 August 2022

nanosynth group plc

("nanosynth", the "Company" or the "Group")

Successful Trial Results

nanosynth, the AIM quoted company specialising in the synthesis and
application of nanoparticles to create new and improve existing products, is
pleased to announce successful trial results with Volz Holdings v.o.s ("Volz")
to enable both companies to develop a standard retro-fit to media production
lines, that allows for  the incorporation of the Company's antiviral
technology into heating, ventilation, and air conditioning ("HVAC")units.

With the completion of the latest trial production run, Volz is now carrying
out process improvements to enable more efficient and consistent production of
safe and reliable media for the end user. The environmental impact of the
treated media was evaluated and determined to be classified as non-hazardous
materials that can be disposed of or recycled without restriction.

The UK's Health and Safety Executive ("HSE") has completed all of its checks
and has approved Pharm 2 Farm Limited ("P2F"), one of the Company's
subsidiaries,  for REACH UK registration (UK Registration, Evaluation,
Authorisation and restriction of Chemicals).  The HSE has now allocated P2F
to the appropriate substance tonnage band, which will allow the production and
distribution of up to 100 tonnes of copper oxide nano-material per year. This
exceeds the Company's preliminary year one forecast copper oxide nano-material
sales requirements for the antiviral HVAC market, enabling the Company to
quickly expand into other antipathogenic projects.

Mark Duffin, CEO of nanosynth commented: "We are delighted by these extremely
positive trial results and the important REACH UK registration which will
allow our partner, Volz, to apply our antiviral technology to all of their
products. This has the potential to lead to wider adoption by the global
filtration industry. A pipeline of interest is already at an advanced stage,
and we are hopeful that this will lead to considerable sales for our first to
market antiviral product."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the
European Union (Withdrawal) Act 2018.  Upon the publication of this
announcement via Regulatory Information Service ('RIS'), this inside is now
considered to be in the public domain.

 

 

ENQUIRIES:

 

 nanosynth group plc                     via IFC Advisory
 Mark Duffin (Chief Executive Officer)

 SP Angel Corporate Finance LLP          +44 20 3470 0470
 Nominated Adviser and Broker
 Stuart Gledhill
 Caroline Rowe

 IFC Advisory Ltd                        +44 20 3934 6630
 Graham Herring
 Zach Cohen

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSDEFISEESELA